| Prev Close | 86.72 |
| Day Low/High | 84.48 / 86.94 |
| 52 Wk Low/High | 66.10 / 87.25 |
| Avg Volume | 9.72M |
Merck & Co. Inc. (MRK)
84.94
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.56B |
| Market Cap | 222.04B |
| EPS | 2.30 |
| P/E Ratio | 40.91 |
| Div & Yield | 2.20 (2.45%) |
Latest News
Jim Cramer: It's Looking Like the 1980s
Kimberly-Clark's performance is nothing to sneeze at, and neither is Coca-Cola's, as higher sales, higher prices and big demand from emerging markets appear to give us a return to the good old days of great senior growth stocks.
Jim Cramer: Don't Play Earnings Season, Invest in It
Here are my five rules for handling earnings season.
I'm Looking at Gilead and Merck for Buy Entry Positions
Let's see if either of these names provide an entry this week.
Merck Could Push Higher in the Weeks and Months Ahead - $100 Is in the Cards
Here's an updated strategy.
Jim Cramer: Why Laggards Like Kohl's, Citi and CVS Can Rise Now
I am neutral on this market, and only a cool off of the hottest stocks can justify a further advance.
Watch These 4 Japanese Drugmakers With Big Coming Events
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
3 Autopilot Funds for a High-Yield Portfolio
This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.
AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
A Handful of Small Biotechs That Make for Merger Chatter
The names include a veterinary drug concern plus companies with successful drugs on the market.
Here's Why I'm Sticking With Merck
The charts are saying MRK is ready to rise.
New Targets for Merck Stock as Charts Point Higher
Investors and traders should approach MRK from the long side.
Here's How I'm Playing Salesforce.com Stock Now
I am no longer as eager to sell these shares as when I discussed this merger pre-opening.
The Nasdaq A/D Line Peaked Months Ago: Danger Will Robinson
'It is not a healthy market when the generals are still going up and the troops are in retreat.'
Jim Cramer: These 7 True Laggards Have Caught Fire
These kinds of stocks are what goes up when there's so little left that hasn't moved that can still be worth buying.
Hey, Apple, Here's What This Shareholder Wants to Hear From You: Market Recon
We also dissect the S&P 500's record run, check out China's latest economic data and take a skeptical glance at an idea floated by a couple Fed officials.
News Surrounds 3 Small Biotechs, With a Merger Claiming One
Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.
Be Careful With Healthcare Stocks Here
Especially when healthcare CEOs discus political issues with analysts and reporters.
Digging Down on the Dow 30
Just 13 of the 30 Dow components are in clear uptrends.
Jim Cramer: Now We've Got FOBS, Fear of Big Sellers
Why are big institutions running and can you outrace them?
'Wonder Dogs' and 'Underdogs': 2 Hot Diggity Twists on the 'Dogs of the Dow'
Selecting the creme de la creme of last year's top dividend dogs generated an average total return of 8.8%.
The Global Macro-Economic Picture, China Watch, Keys to Amazon: Market Recon
The real takeaway for AMZN for me, and the main reason that I am even in the name on a semi-permanent basis, is AWS.
The Technical Oracle of Delphi Says Merck Could Go Up or Down
How do the charts and indicators look ahead of their quarterly release?
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Jim Cramer: Best and Worst of the Dow in 2018
And which stocks are still a buy into 2019.
Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun
And it is happening not a moment too soon.
